{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:34:17Z","timestamp":1781105657151,"version":"3.54.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["EY032458"],"award-info":[{"award-number":["EY032458"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Immunology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.molimm.2024.03.010","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T03:05:28Z","timestamp":1712718328000},"page":"19-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Humanization of a mouse anti-human complement C6 monoclonal antibody as a potential therapeutic for certain complement-mediated diseases"],"prefix":"10.1016","volume":"170","author":[{"given":"Lingjun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Armour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Y.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathi","family":"Mylona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maojing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregers R.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslaw P.","family":"Maciejewki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeti","family":"Bakrania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molimm.2024.03.010_bib1","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1182\/blood.2021012860","article-title":"Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond","volume":"139","author":"Gavriilaki","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.molimm.2024.03.010_bib2","first-page":"1","article-title":"Development, characterization, and in vivo validation of a humanized C6 monoclonal antibody that inhibits the membrane attack complex","author":"Gytz Olesen","year":"2022","journal-title":"J. Innate Immun."},{"key":"10.1016\/j.molimm.2024.03.010_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577767","article-title":"Eculizumab treatment for myasthenia gravis subgroups: 2021 update","volume":"362","author":"Jiao","year":"2022","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.molimm.2024.03.010_bib4","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1111\/trf.13674","article-title":"Peptide inhibitor of complement C1 modulates acute intravascular hemolysis of mismatched red blood cells in rats","volume":"56","author":"Kumar","year":"2016","journal-title":"Transfusion"},{"key":"10.1016\/j.molimm.2024.03.010_bib5","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1182\/bloodadvances.2020001690","article-title":"Development of an anti-human complement C6 monoclonal antibody that inhibits the assembly of membrane attack complexes","volume":"4","author":"Lin","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.molimm.2024.03.010_bib6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40265-019-01068-2","article-title":"Ravulizumab: first global approval","volume":"79","author":"McKeage","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.molimm.2024.03.010_bib7","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molimm.2024.03.010_bib8","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1056\/NEJMra2201664","article-title":"Breakthrough hemolysis in PNH with proximal or terminal complement inhibition","volume":"387","author":"Notaro","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molimm.2024.03.010_bib9","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molimm.2024.03.010_bib10","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1111\/trf.12695","article-title":"Complement inhibition significantly decreases red blood cell lysis in a rat model of acute intravascular hemolysis","volume":"54","author":"Shah","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.molimm.2024.03.010_bib11","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1080\/1744666X.2022.2105205","article-title":"The role of complement and complement therapeutics in neuromyelitis optica spectrum disorders","volume":"18","author":"Stathopoulos","year":"2022","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.molimm.2024.03.010_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719874728","article-title":"Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"10","author":"Stern","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.molimm.2024.03.010_bib13","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2146\/news070038","article-title":"FDA approves drug to treat rare hemoglobinuria","volume":"64","author":"Thompson","year":"2007","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.molimm.2024.03.010_bib14","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1100\/tsw.2010.216","article-title":"Role of C5 activation products in sepsis","volume":"10","author":"Ward","year":"2010","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.molimm.2024.03.010_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.612402","article-title":"Monoclonal antibodies capable of inhibiting complement downstream of C5 in multiple species","volume":"11","author":"Zelek","year":"2020","journal-title":"Front. Immunol."}],"container-title":["Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589024000634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589024000634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T02:49:02Z","timestamp":1738205342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161589024000634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":15,"alternative-id":["S0161589024000634"],"URL":"https:\/\/doi.org\/10.1016\/j.molimm.2024.03.010","relation":{},"ISSN":["0161-5890"],"issn-type":[{"value":"0161-5890","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Humanization of a mouse anti-human complement C6 monoclonal antibody as a potential therapeutic for certain complement-mediated diseases","name":"articletitle","label":"Article Title"},{"value":"Molecular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molimm.2024.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}